<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39560319</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2796</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Journal of internal medicine</Title><ISOAbbreviation>J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Therapeutic BCG vaccine protects against long COVID: The BATTLE randomized clinical trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/joim.20033</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bacillus Calmette-Gu&#xe9;rin (BCG) injected during the COVID-19 convalescence period was safe and enhanced recovery from anosmia and dysgeusia in the acute phase.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To report the long-term results of the BATTLE trial, BCG vaccine in adults with mild COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Design: Double-blind, placebo-controlled, randomized (1:1) clinical trial.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">BCG intradermal vaccine and placebo.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 157 BCG and 142 placebo recipients participated in the 6-month follow-up, and 97 BCG and 95 placebo recipients participated in the 12-month follow-up.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Long COVID symptoms and mechanistic analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BCG reduced hearing problems at 6 months (odds ratio [OR]&#xa0;=&#xa0;0.26) and sleeping, concentration, memory, and vision problems at 12 months (OR&#xa0;=&#xa0;0.45, 0.36, 0.38, and 0.36, respectively). Sensitivity analyses confirmed that long COVID-19 symptoms were reduced at the 6- and 12-month follow-ups (p&#xa0;=&#xa0;0.010 and 0.031, respectively). BCG's crossover interaction paradoxically increased hair loss in women and decreased it in men at 6 months (p&#xa0;=&#xa0;0.032). BCG immunomodulation is likely mediated through inhibition of Fas ligand expression in the blood and increased induction of IL6, IL10, interferon-induced transmembrane protein 3, and angiotensin-converting enzyme 2 in cultured human macrophages.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Long-term follow-up of the BATTLE trial participants revealed that BCG protects against long COVID development if administered within the COVID-19 convalescence period. The response to BCG was subject-specific, including a paradoxical crossover interaction based on sex.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Not tested for previous mycobacterial exposure; loss to follow-up, particularly at 12 months.</AbstractText><CopyrightInformation>&#xa9; 2024 The Association for the Publication of the Journal of Internal Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jalalizadeh</LastName><ForeName>Mehrsa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UroScience, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buosi</LastName><ForeName>Keini</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UroScience, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacomelli</LastName><ForeName>Cristiane F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>UroScience, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leme</LastName><ForeName>Patricia A F</ForeName><Initials>PAF</Initials><AffiliationInfo><Affiliation>UroScience, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>UroScience, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dionato</LastName><ForeName>Franciele A V</ForeName><Initials>FAV</Initials><AffiliationInfo><Affiliation>UroScience, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brito</LastName><ForeName>Wandrey R S</ForeName><Initials>WRS</Initials><AffiliationInfo><Affiliation>Laboratory of Virology, Institute of Biological Sciences, Federal University of Par&#xe1;, Bel&#xe9;m, Par&#xe1;, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunetti</LastName><ForeName>Nat&#xe1;lia S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Biology Institute, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>Aline R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Obesity and Comorbidities Research Center, University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morari</LastName><ForeName>Joseane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Obesity and Comorbidities Research Center, University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagliarone</LastName><ForeName>Ana C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>UroScience, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farias</LastName><ForeName>Alessandro S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Biology Institute, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velloso</LastName><ForeName>Licio A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Obesity and Comorbidities Research Center, University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Queiroz</LastName><ForeName>Maria A F</ForeName><Initials>MAF</Initials><AffiliationInfo><Affiliation>Laboratory of Virology, Institute of Biological Sciences, Federal University of Par&#xe1;, Bel&#xe9;m, Par&#xe1;, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallinoto</LastName><ForeName>Antonio C R</ForeName><Initials>ACR</Initials><AffiliationInfo><Affiliation>Laboratory of Virology, Institute of Biological Sciences, Federal University of Par&#xe1;, Bel&#xe9;m, Par&#xe1;, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajgelman</LastName><ForeName>Marcio C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brazilian Biosciences National Laboratory, LNBio, CNPEM, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Leonardo O</ForeName><Initials>LO</Initials><Identifier Source="ORCID">0000-0003-2092-414X</Identifier><AffiliationInfo><Affiliation>UroScience, State University of Campinas, Unicamp, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ImmunOncology, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>88887.506617/2020-00</GrantID><Agency>Coordination for the Improvement of Higher Education Personnel, CAPES, Federal Government, Brazil</Agency><Country/></Grant><Grant><GrantID>88887.657670/2021-00</GrantID><Agency>Coordination for the Improvement of Higher Education Personnel, CAPES, Federal Government, Brazil</Agency><Country/></Grant><Grant><Agency>General Coordination of the National Immunization Program - CGPNI/DEIDT/SVS/MS</Agency><Country/></Grant><Grant><GrantID>465/2020</GrantID><Agency>Ministry of Health, Brazil</Agency><Country/></Grant><Grant><GrantID>304747/2018-1</GrantID><Agency>National Council for Scientific and Technological Development-CNPq, Research Productivity</Agency><Country/></Grant><Grant><GrantID>310135/2022-2</GrantID><Agency>National Council for Scientific and Technological Development-CNPq, Research Productivity</Agency><Country/></Grant><Grant><GrantID>302935/2021-5</GrantID><Agency>National Council for Scientific and Technological Development-CNPq, Research Productivity</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intern Med</MedlineTA><NlmUniqueID>8904841</NlmUniqueID><ISSNLinking>0954-6820</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">convalescent patients</Keyword><Keyword MajorTopicYN="N">immunomodulation</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">trained immunity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>15</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>15</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>8</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39560319</ArticleId><ArticleId IdType="doi">10.1111/joim.20033</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post&#x2010;COVID&#x2010;19 Condition. A clinical case definition of post&#x2010;COVID&#x2010;19 conditions by a delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;e107. https://doi.org/10.1016/S1473&#x2010;3099(21)00703&#x2010;9.</Citation></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID&#x2010;19. Nat Rev Immunol. 2023;23:618&#x2013;634. https://doi.org/10.1038/s41577&#x2010;023&#x2010;00904&#x2010;7.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146. https://doi.org/10.1038/s41579&#x2010;022&#x2010;00846&#x2010;2.</Citation></Reference><Reference><Citation>Hebert PL, Kumbier KE, Smith VA, Hynes DM, Govier DJ, Wong E, et&#xa0;al. Changes in outpatient health care use after COVID&#x2010;19 infection among veterans. JAMA Netw Open. 2024;7:e2355387. https://doi.org/10.1001/jamanetworkopen.2023.55387.</Citation></Reference><Reference><Citation>Fairbank R. COVID&#x2010;19 patients still have no cure, so these patients are being researched. Nature. 2024;628:26&#x2013;28. https://doi.org/10.1038/d41586&#x2010;024&#x2010;00901&#x2010;3.</Citation></Reference><Reference><Citation>Kim SE. Four years on: the career costs for scientists battling long COVID. Nature. 2024;627:689&#x2013;691. https://doi.org/10.1038/d41586&#x2010;024&#x2010;00819&#x2010;w.</Citation></Reference><Reference><Citation>Di Gennaro F, Belati A, Tulone O, Diella L, Fiore Bavaro D, Bonica R, et&#xa0;al. Incidence of long COVID&#x2010;19 in people with previous SARS&#x2010;Cov2 infection: a systematic review and meta&#x2010;analysis of 120,970 patients. Intern Emerg Med. 2023;18:1573&#x2013;1581. https://doi.org/10.1007/s11739&#x2010;022&#x2010;03164&#x2010;w.</Citation></Reference><Reference><Citation>O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et&#xa0;al. The prevalence and long&#x2010;term health effects of long Covid among hospitalized and nonhospitalized populations: a systematic review and meta&#x2010;analysis. EClinicalMedicine. 2023;55:101762. https://doi.org/10.1016/j.eclinm.2022.101762.</Citation></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et&#xa0;al. Characterizing long COVID: a living systematic review. BMJ Glob Health. 2021;6:e005427. https://doi.org/10.1136/bmjgh&#x2010;2021&#x2010;005427.</Citation></Reference><Reference><Citation>Natarajan A, Shetty A, Delanerolle G, Zeng Y, Zhang Y, Raymont V, et&#xa0;al. A systematic review and meta&#x2010;analysis of long COVID symptoms. Syst Rev. 2023;12:88. https://doi.org/10.1186/s13643&#x2010;023&#x2010;02250&#x2010;0.</Citation></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et&#xa0;al. Risk factors associated with postcovid&#x2010;19 condition: a systematic review and meta&#x2010;analysis. JAMA Intern Med. 2023;183:566&#x2013;580. https://doi.org/10.1001/jamainternmed.2023.0750.</Citation></Reference><Reference><Citation>Jalalizadeh M, Dal Col LSB, Yadollahvandmiandoab R, Reis LO. Bcg immunotherapy: old tool and new concepts. In: Rezaei N., editor. Handbook of cancer and immunology. Berlin: Springer International Publishing; 2022. p. 1&#x2013;23. https://doi.org/10.1007/978&#x2010;3&#x2010;030&#x2010;80962&#x2010;1_199&#x2010;1.</Citation></Reference><Reference><Citation>Jalalizadeh M, Buosi K, Dionato FAV, Dal Col LSB, Giacomelli CF, Ferrari KL, et&#xa0;al. Randomized clinical trial of BCG vaccine in patients with convalescent COVID&#x2010;19: clinical evolution, adverse events, and humoral immune response. J Intern Med. 2022;292:654&#x2013;666. https://doi.org/10.1111/joim.13523.</Citation></Reference><Reference><Citation>Jalalizadeh M, Leme PAF, Buosi K, Dionato FAV, Dal Col LSB, Giacomelli CF, et&#xa0;al. Reactions of healthcare workers (Hcws) and nonhCSs to Bacillus calmette&#x2010;gu&#xe9;rin (Bcg) in the battle trial. Vaccine. 2023;41:6599&#x2013;6606. https://doi.org/10.1016/j.vaccine.2023.09.031.</Citation></Reference><Reference><Citation>Dionato FAV, Jalalizadeh M, Buosi K, Visacri MB, Dal Col LSB, Giacomelli CF, et&#xa0;al. BCG vaccine safety in COVID&#x2010;19 convalescent adults: BATTLE a randomized controlled trial. Vaccine. 2022;40:4603&#x2013;4608. https://doi.org/10.1016/j.vaccine.2022.06.039.</Citation></Reference><Reference><Citation>Jalalizadeh M, Giacomelli CF, Leme PA, Buosi K, Dal Col LS, Dionato FA, et&#xa0;al. Comparison of Bacillus calmette&#x2010;gu&#xe9;rin (Bcg) strains in convalescent COVID&#x2010;19 patients. Immunotherapy. 2023;15:9&#x2013;15. https://doi.org/10.2217/imt&#x2010;2022&#x2010;0048.</Citation></Reference><Reference><Citation>Buosi K, Jalalizadeh M, Maia AR, Morari J, Velloso LA, Reis LO. Modulation of human macrophages by plasma from COVID&#x2010;19 patients following BCG vaccination: BATTLE trial. Int J Gen Med. 2024;17:3107&#x2013;3117. https://doi.org/10.2147/IJGM.S468047.</Citation></Reference><Reference><Citation>Rosli SNZ, Dimeng SR, Shamsuddin F, Mohd Ali MR, Muhamad Hendri NA, Suppiah J, et&#xa0;al. Vero ccl&#x2010;81 and calu&#x2010;3 cell lines as alternative hosts for the isolation and propagation of SARS&#x2010;CoV&#x2010;2 strains isolated from Malaysia. Biomedicines. 2023;11:1658. https://doi.org/10.3390/biomedicines11061658.</Citation></Reference><Reference><Citation>Queiroz MAF, Brito WRDS, Pereira KAS, Pereira LMS, Amoras E da SG, Lima SS, et&#xa0;al. Severe COVID&#x2010;19 and long COVID&#x2010;19 are associated with high expression of STING, cGAS and IFN&#x2010;&#x3b1;. Sci Rep. 2024;14:4974. https://doi.org/10.1038/s41598&#x2010;024&#x2010;55696&#x2010;0.</Citation></Reference><Reference><Citation>Jabalameli N, Rajabi F, Firooz A, Rezaei N. The overlap between genetic susceptibility to COVID&#x2010;19 and skin diseases. Immunol Invest. 2022;51:1087&#x2013;1094. https://doi.org/10.1080/08820139.2021.1876086.</Citation></Reference><Reference><Citation>Leonardi AJ, Argyropoulos CP, Hamdy A, Proenca RB. Understanding the effects of age and t&#x2010;cell differentiation on Covid&#x2010;19 severity: implicating a fas/fasl&#x2010;mediated feed&#x2010;forward controller of t&#x2010;cell differentiation. Front Immunol. 2022;13:853606. https://doi.org/10.3389/fimmu.2022.853606.</Citation></Reference><Reference><Citation>Albert M&#x2010;C, Uranga&#x2010;Murillo I, Arias M, De Miguel D, Pe&#xf1;a N, Montinaro A, et&#xa0;al. Identification of FasL as a crucial host factor driving COVID&#x2010;19 pathology and lethality. Cell Death Differ. 2024;31:544&#x2013;557. https://doi.org/10.1038/s41418&#x2010;024&#x2010;01278&#x2010;6.</Citation></Reference><Reference><Citation>Tedesco S, De Majo F, Kim J, Trenti A, Trevisi L, Fadini GP, et&#xa0;al. Convenience versus biological significance: are PMA&#x2010;differentiated THP&#x2010;1 cells a reliable substitute for blood&#x2010;derived macrophages when studying in vitro polarization? Front Pharmacol. 2018;9:71. https://doi.org/10.3389/fphar.2018.00071.</Citation></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS&#x2010;CoV&#x2010;2 entry into cells. Nat Rev Mol Cell Biol. 2022;23:3&#x2013;20. https://doi.org/10.1038/s41580&#x2010;021&#x2010;00418&#x2010;x.</Citation></Reference><Reference><Citation>Wu D, Dinh TL, Bausk BP, Walt DR. Long&#x2010;term measurements of human inflammatory cytokines reveal complex baseline variations between individuals. Am J Pathol. 2017;187:2620&#x2013;2626. https://doi.org/10.1016/j.ajpath.2017.08.007.</Citation></Reference><Reference><Citation>Togo F, Natelson BH, Adler GK, Ottenweller JE, Goldenberg DL, Struzik ZR, et&#xa0;al. Plasma cytokine fluctuations over time in healthy controls and patients with fibromyalgia. Exp Biol Med (Maywood). 2009;234:232&#x2013;240. https://doi.org/10.3181/0808&#x2010;RM&#x2010;254.</Citation></Reference><Reference><Citation>Salinas Ru&#xed;z J, Montesinos L&#xf3;pez OA, Hern&#xe1;ndez Ram&#xed;rez G, Crossa Hiriart J. Generalized linear mixed models for nonnormal responses. In: Generalized linear mixed models with applications in agriculture and biology. Berlin: Springer International Publishing; 2023. p. 113&#x2013;127. https://doi.org/10.1007/978&#x2010;3&#x2010;031&#x2010;32800&#x2010;8_4.</Citation></Reference><Reference><Citation>Zakia H, Pradana K, Iskandar S. Risk factors for psychiatric symptoms in patients with long COVID: a systematic review. PLoS ONE. 2023;18:e0284075. https://doi.org/10.1371/journal.pone.0284075.</Citation></Reference><Reference><Citation>Chester AC. Chronic rhinosinusitis and fatigue: a common but underappreciated association. Am J Med. 2008;121:e13. https://doi.org/10.1016/j.amjmed.2008.04.041.</Citation></Reference><Reference><Citation>Popescu MN, Berteanu M, Beiu C, Popa LG, Mihai MM, Iliescu MG, et&#xa0;al. Complementary strategies to promote hair regrowth in post&#x2010;COVID&#x2010;19 telogen effluvium. Clin Cosmet Investig Dermatol. 2022;15:735&#x2013;743. https://doi.org/10.2147/CCID.S359052.</Citation></Reference><Reference><Citation>Rojas M, Rodr&#xed;guez Y, Monsalve DM, Acosta&#x2010;Ampudia Y, Camacho B, Gallo JE, et&#xa0;al. Convalescent plasma in COVID&#x2010;19: possible mechanisms of action. Autoimmun Rev. 2020;19:102554. https://doi.org/10.1016/j.autrev.2020.102554.</Citation></Reference><Reference><Citation>Soares SR, da Silva Torres MK, Lima SS, de Sarges KML, Santos EFD, de Brito MTFM, et&#xa0;al. Antibody response to SARS&#x2010;CoV&#x2010;2 spike and nucleocapsid proteins in patients with different COVID&#x2010;19 clinical profiles. Viruses. 2023;15:898. https://doi.org/10.3390/v15040898.</Citation></Reference><Reference><Citation>Santos AP, Werneck GL, Dalvi APR, Dos Santos CC, Tierno PFGMM, Condelo HS, et&#xa0;al. The effect of BCG vaccination on infection and antibody levels against SARS&#x2010;CoV&#x2010;2&#x2013;The results of ProBCG: a multicenter randomized clinical trial in Brazil. Int J Infect Dis. 2023;130:8&#x2013;16. https://doi.org/10.1016/j.ijid.2023.02.014.</Citation></Reference><Reference><Citation>Giamarellos&#x2010;Bourboulis EJ, Tsilika M, Moorlag S, Antonakos N, Kotsaki A, Dom&#xed;nguez&#x2010;Andr&#xe9;s J, et&#xa0;al. Activate: randomized clinical trial of BCG vaccination against infection in the elderly. Cell. 2020;183:315&#x2013;323. https://doi.org/10.1016/j.cell.2020.08.051.</Citation></Reference><Reference><Citation>Noble CCA, Messina NL, Pittet LF, Curtis N. Interpreting the results of trials of BCG vaccination for protection against COVID&#x2010;19. J Infect Dis. 2023;228:1467&#x2013;1478. https://doi.org/10.1093/infdis/jiad316.</Citation></Reference><Reference><Citation>Upton CM, van Wijk, RC, Mockeliunas L, Simonsson USH, McHarry K, van den Hoogen, G, et&#xa0;al. Safety and efficacy of BCG revaccination in relation to COVID&#x2010;19 morbidity in healthcare workers: a double&#x2010;blind, randomized, controlled, phase 3 trial. EClinicalMedicine. 2022;48:101414. https://doi.org/10.1016/j.eclinm.2022.101414.</Citation></Reference><Reference><Citation>Pittet LF, Messina NL, Orsini F, Moore CL, Abruzzo V, Barry S, et&#xa0;al. Randomized trial of bcg vaccine to protect against Covid&#x2010;19 in health care workers. N Engl J Med. 2023;388:1582&#x2013;1596. https://doi.org/10.1056/NEJMoa2212616.</Citation></Reference><Reference><Citation>da Costa CG, Jalalizadeh M, Yadollahvandmiandoab R, Buosi K, Reis LO. Effect of bcg on respiratory complications caused by Covid&#x2010;19: a scoping review. Int J Gen Med. 2022;15:8727&#x2013;8741. https://doi.org/10.2147/IJGM.S393861.</Citation></Reference><Reference><Citation>Dos Santos PCP, Messina NL, de Oliveira RD, da Silva PV, Puga MAM, Dalcolmo M, et&#xa0;al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health&#x2010;care workers: a nested clinical trial. Lancet Infect Dis. 2024;24:594&#x2013;601. https://doi.org/10.1016/S1473&#x2010;3099(23)00818&#x2010;6.</Citation></Reference><Reference><Citation>Madsen AMR, Schaltz&#x2010;Buchholzer F, Nielsen S, Benfield T, Bjerregaard&#x2010;Andersen M, Dalgaard LS, et&#xa0;al. Using BCG vaccine to enhance nonspecific protection of health care workers during the COVID&#x2010;19 pandemic: a randomized controlled trial. J Infect Dis. 2024;229:384&#x2013;393. https://doi.org/10.1093/infdis/jiad422.</Citation></Reference><Reference><Citation>Ohrui T, Nakayama K, Fukushima T, Chiba H, Sasaki H. [Prevention of elderly pneumonia by pneumococcal, influenza and BCG vaccinations]. Nihon Ronen Igakkai Zasshi. 2005;42:34&#x2013;36. https://doi.org/10.3143/geriatrics.42.34.</Citation></Reference><Reference><Citation>Netea MG, Ziogas A, Benn CS, Giamarellos&#x2010;Bourboulis EJ, Joosten LAB, Arditi M, et&#xa0;al. The role of trained immunity in COVID&#x2010;19: lessons for the next pandemic. Cell Host Microbe. 2023;31:890&#x2013;901. https://doi.org/10.1016/j.chom.2023.05.004.</Citation></Reference><Reference><Citation>Gomes DGE. Should I use fixed effects or random effects when I have fewer than five levels of a grouping factor in a mixed&#x2010;effects model? PeerJ. 2022;10:e12794. https://doi.org/10.7717/peerj.12794.</Citation></Reference><Reference><Citation>Dos Santos MF, Devalle S, Aran V, Capra D, Roque NR, Coelho&#x2010;Aguiar J de M, et&#xa0;al. Neuromechanisms of SARS&#x2010;CoV&#x2010;2: a review. Front Neuroanat. 2020;14:37. https://doi.org/10.3389/fnana.2020.00037.</Citation></Reference><Reference><Citation>Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, et&#xa0;al. Development of ACE2 autoantibodies after SARS&#x2010;CoV&#x2010;2 infection. PLoS ONE. 2021;16:e0257016. https://doi.org/10.1371/journal.pone.0257016.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Author correction: long COVID&#x2010;19: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:408. https://doi.org/10.1038/s41579&#x2010;023&#x2010;00896&#x2010;0.</Citation></Reference><Reference><Citation>Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et&#xa0;al. Cytokine&#x2010;associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445&#x2013;452. https://doi.org/10.1001/archpsyc.58.5.445.</Citation></Reference><Reference><Citation>Cecchetto A, Guarnieri G, Torreggiani G, Vianello A, Baroni G, Palermo C, et&#xa0;al. Dyspnea in postacute covid&#x2010;19: a multiparametric cardiopulmonary evaluation. J Clin Med. 2023;12:4658. https://doi.org/10.3390/jcm12144658.</Citation></Reference><Reference><Citation>Grewal JS, Carlsten C, Johnston JC, Shah AS, Wong AW, Ryerson CJ. Post&#x2010;COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort. BMC Pulm Med. 2023;23:84. https://doi.org/10.1186/s12890&#x2010;023&#x2010;02376&#x2010;w.</Citation></Reference><Reference><Citation>Rahman A, Tiwari A, Narula J, Hickling T. Importance of feedback and feedforward loops to adaptive immune response modeling. CPT Pharmacometrics Syst Pharmacol. 2018;7:621&#x2013;628. https://doi.org/10.1002/psp4.12352.</Citation></Reference><Reference><Citation>Mangan S, Zaslaver A, Alon U. The coherent feedforward loop serves as a sign&#x2010;sensitive delay element in transcription networks. J Mol Biol. 2003;334:197&#x2013;204. https://doi.org/10.1016/j.jmb.2003.09.049.</Citation></Reference><Reference><Citation>Hong J, Brandt N, Abdul&#x2010;Rahman F, Yang A, Hughes T, Gresham D. An incoherent feedforward loop facilitates adaptive tuning of gene expression. Elife. 2018;7:e32323. https://doi.org/10.7554/eLife.32323.</Citation></Reference><Reference><Citation>Goentoro L, Shoval O, Kirschner MW, Alon U. The incoherent feedforward loop can provide fold&#x2010;change detection in gene regulation. Mol Cell. 2009;36:894&#x2013;899. https://doi.org/10.1016/j.molcel.2009.11.018.</Citation></Reference><Reference><Citation>Brandes M, Klauschen F, Kuchen S, Germain RN. A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. Cell. 2013;154:197&#x2013;212. https://doi.org/10.1016/j.cell.2013.06.013.</Citation></Reference><Reference><Citation>Wierman ME. Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ. 2007;31:26&#x2013;33. https://doi.org/10.1152/advan.00086.2006.</Citation></Reference><Reference><Citation>Nieuwenhuizen NE, Zyla J, Zedler U, Bandermann S, Abu Abed U, Brinkmann V, et&#xa0;al. Weaker protection against tuberculosis in BCG&#x2010;vaccinated male 129 S2 mice compared to females. Vaccine. 2021;39:7253&#x2013;7264. https://doi.org/10.1016/j.vaccine.2021.09.039.</Citation></Reference><Reference><Citation>Rhodes SJ, Knight GM, Fielding K, Scriba TJ, Pathan AA, McShane H, et&#xa0;al. Individual&#x2010;level factors associated with variation in mycobacterial&#x2010;specific immune response: sex and previous BCG vaccination status. Tuberculosis (Edinb). 2016;96:37&#x2013;43. https://doi.org/10.1016/j.tube.2015.10.002.</Citation></Reference><Reference><Citation>Kleynhans L, Du Plessis N, Black GF, Loxton AG, Kidd M, van Helden PD, et&#xa0;al. Medroxyprogesterone acetate alters Mycobacterium bovis BCG&#x2010;induced cytokine production in peripheral blood mononuclear cells of contraceptive users. PLoS ONE. 2011;6:e24639. https://doi.org/10.1371/journal.pone.0024639.</Citation></Reference><Reference><Citation>Zaafour M, Fraia A, Frih H, Guernine S, Djemli S, Rachedi BA. Assessment of steroids changes (Testosterone and estradiol) after bcg inoculation in sciatic nerve injury model(Male wistar rat). GV. 2015;14:805&#x2013;812. https://doi.org/10.5829/idosi.gv.2015.14.06.94269.</Citation></Reference><Reference><Citation>Mizushima T, Jiang G, Kawahara T, Li P, Han B, Inoue S, et&#xa0;al. Androgen receptor signaling reduces the efficacy of bacillus calmette&#x2010;gu&#xe9;rin therapy for bladder cancer by modulating rab27b&#x2010;induced exocytosis. Mol Cancer Ther. 2020;19:1930&#x2013;1942. https://doi.org/10.1158/1535&#x2013;7163.MCT&#x2010;20&#x2010;0050.</Citation></Reference><Reference><Citation>Reis LO, Salustiano ACC, Capibaribe DM, Kiehl IGA, Denardi F. Castration immunoregulates toll&#x2010;like receptor&#x2010;4 in male bladder cancer. Int Urol Nephrol. 2022;54:2845&#x2013;2853. https://doi.org/10.1007/s11255&#x2010;022&#x2010;03336&#x2010;9.</Citation></Reference><Reference><Citation>Khalifa SE, Riyadh LK, Auroba A&#x2010;S. BCG immunotherapy in patients with alopecia areata. Yemeni Med Sciences J. 2003;3:15&#x2013;19.</Citation></Reference><Reference><Citation>K&#xfc;htreiber WM, Faustman DL. BCG therapy for type 1 diabetes: restoration of balanced immunity and metabolism. Trends Endocrinol Metab. 2019;30:80&#x2013;92. https://doi.org/10.1016/j.tem.2018.11.006.</Citation></Reference><Reference><Citation>Greenblatt CL, Lathe R. Vaccines and dementia: part I. non&#x2010;specific immune boosting with BCG: history, ligands, and receptors. J Alzheimers Dis. 2024;98:343&#x2013;360. https://doi.org/10.3233/JAD&#x2010;231315.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>